drug controller general of india (dcgi)
Cadila Healthcare gets DCGI nod to conduct phase 3 trials for two-dose COVID vaccine
The company has got the permission for conduct of phase III trials for two-dose Covid vaccine, Cadila Healthcare said in a regulatory filing
LifeCell gets DCGI nod for clinical trial of cell therapy to treat COVID patients
The company has set up a manufacturing facility at its Chennai campus that will further bolster its biologics manufacturing capabilities
Mylan Pharma to launch remdesivir in India at Rs 4,800 per 100 mg vial
The drug will be launched under the brand name Desrem in India and will be available to patients later this month
Hetero gets DCGI nod to launch Remdesivir for COVID-19 treatment
The drug will be available in 100 mg vial which will be administered intravenously in a hospital under healthcare practitioner supervision
India's Glenmark to conduct trials for potential Covid19 drug
Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%
India will import drugs with less than 60 pc shelf life, condition apply
Health ministry has instructed to take various steps to ensure availability of a sufficient quantity of drugs in the domestic retail market